Amylin and its analogs: A friend or foe for the treatment of Alzheimer's disease?

Frontiers in Aging Neuroscience

Volumn 6, Issue JUL, 2014, Pages

  Qiu, Wei Qiao ^a   Zhu, Haihao ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLIN DERIVATIVE; GLUCOSE; INSULINASE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; ATTENTION; BETA SHEET; BLOOD BRAIN BARRIER; CELL GROWTH; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DEPTH PERCEPTION; DISEASE MODEL; EXECUTIVE FUNCTION; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; MEMORY; MENTAL CONCENTRATION; NERVE REGENERATION; NEUROFIBRILLARY TANGLE; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; VERBAL COMMUNICATION;

EID: 84904615046     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00186     Document Type: Article

References (99)

1. Adler BL, Yarchoan M, Hwang HM, Louneva N, Blair JA, Palm R, Smith MA, Lee HG, Arnold SE, Casadesus G. 2014. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol Aging 35(4): 793-801.
2. Ahren B, Oosterwijk C, Lips CJ, Hoppener JW. 1998. Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. Diabetologia 41(11): 1374-1380.
3. Alam T, Chen L, Ogawa A, Leffert JD, Unger RH, Luskey KL. 1992. Coordinate regulation of amylin and insulin expression in response to hypoglycemia and fasting. Diabetes 41(4): 508-514.
4. Andreetto E, Yan LM, Caporale A, Kapurniotu A. 2011. Dissecting the role of single regions of an IAPP mimic and IAPP in inhibition of Abeta40 amyloid formation and cytotoxicity. Chembiochem 12(9): 1313-1322.
5. Andreetto E, Yan LM, Tatarek-Nossol M, Velkova A, Frank R, Kapurniotu A. 2010. Identification of hot regions of the Abeta-IAPP interaction interface as highaffinity binding sites in both cross- and self-association. Angew Chem Int Ed Engl 49(17): 3081-3085.
6. Andrikopoulos S, Hull RL, Verchere CB, Wang F, Wilbur SM, Wight TN, Marzban L, Kahn SE. 2004. Extended life span is associated with insulin resistance in a transgenic mouse model of insulinoma secreting human islet amyloid polypeptide. Am J Physiol Endocrinol Metab 286(3): E418-424.
7. Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C. 2007. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebocontrolled, dose-escalation study. J Clin Endocrinol Metab 92(8): 2977-2983.
8. Banks WA, Kastin AJ. 1998. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 19(5): 883-889.
9. Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB. 1995. Permeability of the blood-brain barrier to amylin. Life Sci 57(22): 1993-2001.
10. Baraka A, ElGhotny S. 2010. Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats. Eur J Pharmacol 641(2-3): 123-127.
11. Bennett RG, Hamel FG, Duckworth WC. 2003. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 52(9): 2315- 2320.
12. Boyle CN, Lutz TA. 2011. Amylinergic control of food intake in lean and obese rodents. Physiol Behav 105(1): 129-137.
13. Bryant NJ, Govers R, James DE. 2002. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 3(4): 267-277.
14. Chang CL, Roh J, Hsu SY. 2004. Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: a comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides 25(10): 1633-1642.
15. Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, Sexton PM. 1999. Multiple amylin receptors arise from receptor activity modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56(1): 235-242.
16. Clementi G, Caruso A, Cutuli VM, Prato A, de Bernardis E, Fiore CE, Amico-Roxas M. 1995. Anti-inflammatory activity of amylin and CGRP in different experimental models of inflammation. Life Sci 57(14): PL193-197.
17. Colburn WA, Gottlieb AB, Koda J, Kolterman OG. 1996. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol 36(1): 13-24.
18. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. 1987. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84(23): 8628-8632.
19. Cornish J, Callon KE, King AR, Cooper GJ, Reid IR. 1998. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 275(4 Pt 1): E694-699.
20. Danysz W, Parsons CG. 2012. Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol 167(2): 324-352.
21. Davey RA, Turner AG, McManus JF, Chiu WS, Tjahyono F, Moore AJ, Atkins GJ, Anderson PH, Ma C, Glatt V et al. 2008. Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J Bone Miner Res 23(8): 1182- 1193.
22. de Koning EJ, Morris ER, Hofhuis FM, Posthuma G, Hoppener JW, Morris JF, Capel PJ, Clark A, Verbeek JS. 1994. Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 91(18): 8467-8471.
23. de Tullio MB, Castelletto V, Hamley IW, Martino Adami PV, Morelli L, Castano EM. 2013. Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic abeta peptide aggregates. PLoS One 8(4): e59113.
24. DeToma AS, Salamekh S, Ramamoorthy A, Lim MH. 2012. Misfolded proteins in Alzheimer's disease and type II diabetes. Chem Soc Rev 41(2): 608-621.
25. Dunkel P, Chai CL, Sperlagh B, Huleatt PB, Matyus P. 2012. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs 21(9): 1267-1308.
26. Edvinsson L, Goadsby PJ, Uddman R. 2001. Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. ScientificWorldJournal 1: 168-180.
27. Fehmann HC, Weber V, Goke R, Goke B, Arnold R. 1990. Cosecretion of amylin and insulin from isolated rat pancreas. FEBS Lett 262(2): 279-281.
28. Fu W, Ruangkittisakul A, MacTavish D, Shi JY, Ballanyi K, Jhamandas JH. 2012. Amyloid beta (Abeta) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem 287(22): 18820- 18830.
29. Fukuda T, Hirai Y, Maezawa H, Kitagawa Y, Funahashi M. 2013. Electrophysiologically identified presynaptic mechanisms underlying amylinergic modulation of area postrema neuronal excitability in rat brain slices. Brain Res 1494: 9-16.
30. Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Tornell J, Westermark P, Sundler F, Ahren B, Betsholtz C. 1998a. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 250(2): 271-277.
31. Gebre-Medhin S, Mulder H, Zhang Y, Sundler F, Betsholtz C. 1998b. Reduced nociceptive behavior in islet amyloid polypeptide (amylin) knockout mice. Brain Res Mol Brain Res 63(1): 180-183.
32. Gebre-Medhin S, Olofsson C, Mulder H. 2000. Islet amyloid polypeptide in the islets of Langerhans: friend or foe? Diabetologia 43(6): 687-695.
33. Gingell JJ, Burns ER, Hay DL. 2013. Activity of pramlintide, rat and human amylin but not Abeta1-42 at human amylin receptors. Endocrinology.
34. Gotz J, Ittner LM, Lim YA. 2009. Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 66(8): 1321-1325.
35. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580): 353-356.
36. Hom JT, Estridge T, Pechous P, Hyslop PA. 1995. The amyloidogenic peptide human amylin augments the inflammatory activities of eosinophils. J Leukoc Biol 58(5): 526-532.
37. Hoppener JW, Ahren B, Lips CJ. 2000. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343(6): 411-419.
38. Hoppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH, Vroom TM, Ahren B, Lips CJ. 1999. Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42(4): 427-434.
39. Hoppener JW, Oosterwijk C, van Hulst KL, Verbeek JS, Capel PJ, de Koning EJ, Clark A, Jansz HS, Lips CJ. 1994. Molecular physiology of the islet amyloid polypeptide (IAPP)/amylin gene in man, rat, and transgenic mice. J Cell Biochem 55 Suppl: 39-53.
40. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M, Prigeon RL, Kahn SE. 2003. Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52(2): 372-379.
41. Hull RL, Westermark GT, Westermark P, Kahn SE. 2004. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89(8): 3629-3643.
42. Imfeld P, Bodmer M, Jick SS, Meier CR. 2012. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc 60(5): 916-921.
43. Jackson K, Barisone GA, Diaz E, Jin LW, Decarli C, Despa F. 2013. Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann Neurol.
44. Johnson KA, Fox NC, Sperling RA, Klunk WE. 2012. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2(4): a006213.
45. Kapurniotu A, Bernhagen J, Greenfield N, Al-Abed Y, Teichberg S, Frank RW, Voelter W, Bucala R. 1998. Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. Eur J Biochem 251(1-2): 208-216.
46. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R. 1994. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 37(2): 188-194.
47. Kraemer RR, Acevedo EO, Synovitz LB, Durand RJ, Johnson LG, Petrella E, Fineman MS, Gimpel T, Castracane VD. 2002. Glucoregulatory endocrine responses to intermittent exercise of different intensities: plasma changes in a pancreatic betacell peptide, amylin. Metabolism 51(5): 657-663.
48. Lim YA, Ittner LM, Lim YL, Gotz J. 2008. Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett 582(15): 2188-2194.
49. Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P. 1989. Colocalization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32(4): 240-244.
50. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z et al. 2010. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 11(10): 897-904.
51. Min DK, Tuor UI, Koopmans HS, Chelikani PK. 2011. Changes in differential functional magnetic resonance signals in the rodent brain elicited by mixed-nutrient or protein-enriched meals. Gastroenterology 141(5): 1832-1841.
52. Mollet A, Gilg S, Riediger T, Lutz TA. 2004. Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats. Physiol Behav 81(1): 149- 155.
53. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, Woodward M, Boundy K, Ellis KA, Bush AI et al. 2013. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36(10): 2981-2987.
54. Moriarty DF, Raleigh DP. 1999. Effects of sequential proline substitutions on amyloid formation by human amylin20-29. Biochemistry 38(6): 1811-1818.
55. Mulder H, Gebre-Medhin S, Betsholtz C, Sundler F, Ahren B. 2000. Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxaninduced diabetes. Am J Physiol Endocrinol Metab 278(4): E684-691.
56. Mulder H, Jongsma H, Zhang Y, Gebre-Medhin S, Sundler F, Danielsen N. 1999. Pituitary adenylate cyclase-activating polypeptide and islet amyloid polypeptide in primary sensory neurons: functional implications from plasticity in expression on nerve injury and inflammation. Mol Neurobiol 19(3): 229-253.
57. Mulder H, Leckstrom A, Uddman R, Ekblad E, Westermark P, Sundler F. 1995. Islet amyloid polypeptide (amylin) is expressed in sensory neurons. J Neurosci 15(11): 7625-7632.
58. Mulder H, Lindh AC, Ekblad E, Westermark P, Sundler F. 1994. Islet amyloid polypeptide is expressed in endocrine cells of the gastric mucosa in the rat and mouse. Gastroenterology 107(3): 712-719.
59. Mulder H, Zhang Y, Danielsen N, Sundler F. 1997. Islet amyloid polypeptide and calcitonin gene-related peptide expression are upregulated in lumbar dorsal root ganglia after unilateral adjuvant-induced inflammation in the rat paw. Brain Res Mol Brain Res 50(1-2): 127-135.
60. Nishi M, Sanke T, Seino S, Eddy RL, Fan YS, Byers MG, Shows TB, Bell GI, Steiner DF. 1989. Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history. Mol Endocrinol 3(11): 1775- 1781.
61. Nyholm B, Fineman MS, Koda JE, Schmitz O. 1998. Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulindependent diabetes mellitus. Horm Metab Res 30(4): 206-212.
62. Olsson M, Herrington MK, Reidelberger RD, Permert J, Arnelo U. 2007. Comparison of the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat. Peptides 28(7): 1416-1423.
63. Opie EL. 1901. ON THE RELATION OF CHRONIC INTERSTITIAL PANCREATITIS TO THE ISLANDS OF LANGERHANS AND TO DIABETES MELUTUS. J Exp Med 5(4): 397-428.
64. Pencek R, Roddy T, Peters Y, De Young MB, Herrmann K, Meller L, Nguyen H, Chen S, Lutz K. 2010. Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study. Diabetes Obes Metab 12(6): 548-551.
65. Pillay K, Govender P. 2013. Amylin uncovered: a review on the polypeptide responsible for type II diabetes. Biomed Res Int 2013: 826706.
66. Potes CS, Boyle CN, Wookey PJ, Riediger T, Lutz TA. 2012. Involvement of the extracellular signal-regulated kinase 1/2 signaling pathway in amylin's eating inhibitory effect. Am J Physiol Regul Integr Comp Physiol 302(3): R340-351.
67. Potes CS, Lutz TA. 2010. Brainstem mechanisms of amylin-induced anorexia. Physiol Behav 100(5): 511-518.
68. Qiu WQ, Wallack M, Dean M, Liebson E, Mwamburi M, Zhu H. 2014. Association between Amylin and Amyloid-beta Peptides in Plasma in the Context of Apolipoprotein E4 Allele. PLoS One 9(2): e88063.
69. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. 1998. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273(49): 32730- 32738.
70. Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC. 1998. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM. Diabetes Care 21(5): 810-816.
71. Reifert J, Hartung-Cranston D, Feinstein SC. 2011. Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation. J Biol Chem 286(23): 20797-20811.
72. Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. 2007. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 56(1): 65-71.
73. Roth JD. 2013. Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology. Curr Opin Endocrinol Diabetes Obes 20(1): 8-13.
74. Roth JD, Erickson MR, Chen S, Parkes DG. 2012. GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Br J Pharmacol 166(1): 121-136.
75. Roth JD, Roth JD, Erickson MR, Chen S, Parkes DG. 2013. Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology
76. GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Curr Opin Endocrinol Diabetes Obes 20(1): 8-13.
77. Rowland NE, Crews EC, Gentry RM. 1997. Comparison of Fos induced in rat brain by GLP-1 and amylin. Regul Pept 71(3): 171-174.
78. Seeliger J, Evers F, Jeworrek C, Kapoor S, Weise K, Andreetto E, Tolan M, Kapurniotu A, Winter R. 2012. Cross-amyloid interaction of Abeta and IAPP at lipid membranes. Angew Chem Int Ed Engl 51(3): 679-683.
79. Selkoe DJ. 2008. Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handb Clin Neurol 89: 245-260.
80. Sellin D, Yan LM, Kapurniotu A, Winter R. 2010. Suppression of IAPP fibrillation at anionic lipid membranes via IAPP-derived amyloid inhibitors and insulin. Biophys Chem 150(1-3): 73-79.
81. Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL. 2009. Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov Today 14(7-8): 413-419.
82. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT et al. 2013. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 14(8): 812- 820.
83. Shen Y, Joachimiak A, Rosner MR, Tang WJ. 2006. Structures of human insulindegrading enzyme reveal a new substrate recognition mechanism. Nature 443(7113): 870-874.
84. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. 1997. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 273(3): 729-739.
85. Trevaskis JL, Turek VF, Wittmer C, Griffin PS, Wilson JK, Reynolds JM, Zhao Y, Mack CM, Parkes DG, Roth JD. 2010. Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats. Endocrinology 151(12): 5657-5668.
86. Turek VF, Trevaskis JL, Levin BE, Dunn-Meynell AA, Irani B, Gu G, Wittmer C, Griffin PS, Vu C, Parkes DG et al. 2010. Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 151(1): 143-152.
87. Vine W, Blase E, Koda J, Young A. 1998. Plasma amylin concentrations in fasted and fed rats quantified by a monoclonal immunoenzymometric assay. Horm Metab Res 30(9): 581-585.
88. Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D et al. 2009. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 23(2): 91-101.
89. Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P. 2000. Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med 6(12): 998-1007.
90. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH. 1987. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84(11): 3881-3885.
91. Westfall TC, Curfman-Falvey M. 1995. Amylin-induced relaxation of the perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors. J Cardiovasc Pharmacol 26(6): 932-936.
92. Wickbom J, Herrington MK, Permert J, Jansson A, Arnelo U. 2008. Gastric emptying in response to IAPP and CCK in rats with subdiaphragmatic afferent vagotomy. Regul Pept 148(1-3): 21-25.
93. Wimalawansa SJ. 1997. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol 11(2-3): 167-239.
94. Yan LM, Velkova A, Kapurniotu A. 2013a. Molecular Characterization of the Hetero- Assembly of beta-Amyloid Peptide with Islet Amyloid Polypeptide. Curr Pharm Des.
95. Yan LM, Velkova A, Tatarek-Nossol M, Andreetto E, Kapurniotu A. 2007. IAPP mimic blocks Abeta cytotoxic self-assembly: cross-suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Angew Chem Int Ed Engl 46(8): 1246-1252.
96. Yan LM, Velkova A, Tatarek-Nossol M, Rammes G, Sibaev A, Andreetto E, Kracklauer M, Bakou M, Malideli E, Goke B et al. 2013b. Selectively N-Methylated Soluble IAPP Mimics as Potent IAPP Receptor Agonists and Nanomolar Inhibitors of Cytotoxic Self-Assembly of Both IAPP and Abeta40. Angew Chem Int Ed Engl 52(39): 10378-10383.
97. Young A. 2005. Central nervous system and other effects. Adv Pharmacol 52: 281-288.
98. Zapecka-Dubno B, Czyzyk A, Dworak A, Bak MI. 1999. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2). Arzneimittelforschung 49(4): 330-334.
99. Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, Hur JY, Zheng H, Li H, Fine R et al. 2014. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. Mol Psychiatry.